Johnson Pharmacare (532154) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the year ended March 31, 2025, were approved with an unmodified audit opinion.

• Board meeting on May 23, 2025, reviewed and approved the results and audit report.

Financial highlights

• Revenue from operations was nil for the year ended March 31, 2025, unchanged from the previous year.

• Net loss after tax for FY25 was Rs. 58.38 lakhs, compared to a net loss of Rs. 19.62 lakhs in FY24.

• Exceptional items of Rs. 17.16 lakhs related to a SEBI penalty impacted FY25 results.

• Basic and diluted EPS for FY25 stood at (0.01), unchanged from the previous year.

Key financial ratios and metrics

• Paid-up equity share capital remained at Rs. 5,500 lakhs as of March 31, 2025.

• Other equity declined to Rs. 116.91 lakhs from Rs. 175.30 lakhs year-over-year.

• Total assets decreased to Rs. 5,792.59 lakhs from Rs. 5,982.98 lakhs year-over-year.

• Non-current borrowings reduced to Rs. 60.54 lakhs from Rs. 195.04 lakhs year-over-year.